Form 4 for PRLD Prelude Therapeutics Inc
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-14 · accession 0001562180-25-002541 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-03-18 | 2025-03-14+ | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $0.75 | +39.1K | 1.29M | +3% | +$29.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-17 | P | A | 9,106 | $0.75 | 1,303,880 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7496 to $0.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. |
| 2 | Common | Common Stock | 2025-03-14 | P | A | 29,999 | $0.75 | 1,294,774 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7746 to $0.7782, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. |